Marksans Pharma Ltd
NSE:MARKSANS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Marksans Pharma Ltd
NSE:MARKSANS
|
IN |
|
U
|
Uniqa Insurance Group AG
VSE:UQA
|
AT |
|
I
|
Interlink Telecom PCL
SET:ITEL
|
TH |
|
ANI Pharmaceuticals Inc
NASDAQ:ANIP
|
US |
|
O
|
Orezone Gold Corp
TSX:ORE
|
CA |
|
Paladin Energy Ltd
ASX:PDN
|
AU |
|
Jowell Global Ltd
NASDAQ:JWEL
|
CN |
|
X Fab Silicon Foundries EV
PAR:XFAB
|
BE |
|
Ryan Specialty Group Holdings Inc
NYSE:RYAN
|
US |
|
N
|
Novartis AG
XMUN:NOT
|
CH |
|
Carlsberg A/S
OTC:CABJF
|
DK |
|
Telus International Cda Inc
TSX:TIXT
|
CA |
|
C
|
China Petroleum & Chemical Corp
SWB:CHU
|
CN |
|
N
|
Newell Brands Inc
F:NWL
|
US |
|
Rushil Decor Ltd
NSE:RUSHIL
|
IN |
|
Arhaus Inc
NASDAQ:ARHS
|
US |
Wall St Price Targets
MARKSANS Price Targets Summary
Marksans Pharma Ltd
According to Wall Street analysts, the average 1-year price target for MARKSANS is 229.5 INR with a low forecast of 212.1 INR and a high forecast of 252 INR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is MARKSANS's stock price target?
Price Target
229.5
INR
According to Wall Street analysts, the average 1-year price target for MARKSANS is 229.5 INR with a low forecast of 212.1 INR and a high forecast of 252 INR.
What is the Revenue forecast for Marksans Pharma Ltd?
Projected CAGR
16%
Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 4 years is 16%.
What is the Operating Income forecast for Marksans Pharma Ltd?
Projected CAGR
23%
The compound annual growth rate for Operating Income over the next 4 years is 23%.
What is the Net Income forecast for Marksans Pharma Ltd?
Projected CAGR
20%
The compound annual growth rate for Net Income over the next 4 years is 20%.
